Why FDA or CE Clearances Fail to Register Aesthetic Devices in China, Korea, and Brazil

A deep regulatory analysis of aesthetic device classification and registration pathway divergence across the US, EU, China, South Korea, and Brazil, mapping sequencing strategies and all-in costs.

Introduction: The Global Aesthetics Expansion Problem

The global market for medical aesthetics is experiencing an unprecedented surge. According to the International Society of Aesthetic Plastic Surgery (ISAPS) 2024 global survey, practitioners recorded 37.9 million aesthetic and cosmetic procedures worldwide, reflecting a 42.5% increase over four years. Non-surgical procedures reached 20.5 million, heavily dominated by the two leading injectables—botulinum toxin and hyaluronic acid (HA) fillers—which combined to 14.1 million procedures (7.8 million botulinum toxin and 6.3 million HA fillers, with HA fillers expanding at a steady 5.2% year-on-year rate).

This clinical demand has triggered a parallel wave of cross-border device registrations. Device developers holding an FDA clearance or an EU CE mark are moving aggressively to commercialize their products in high-growth aesthetics markets: China, South Korea, and Brazil.

However, many first-time registrants hit a regulatory wall. They operate under the false assumption that a US FDA 510(k) clearance or a European CE mark functions as an all-access key that can be easily translated into local registrations. In reality, the global regulatory landscape is highly fragmented:

Divergent Risk Classification: The exact same aesthetic device is classified under entirely different risk tiers across major jurisdictions.
Asymmetric Reliance Lanes: While some regulators offer expedited review pathways based on prior foreign approvals, these reliance routes are asymmetric and exclude the CE mark in key regions.
Strict Clinical and Rep Barriers: Several high-growth markets require domestic clinical trials for specific high-risk product categories — for example, China's Class III HA fillers under the CMDE 2026 guideline — plus type testing and a legally responsible in-country representative who holds the registration. Foreign clinical data is often accepted in whole or in part in markets such as Japan and Korea, so the clinical-data burden is product- and jurisdiction-specific rather than universal.

To help manufacturers navigate these divergent rulebooks, we have analyzed a cross-market map showing how the same aesthetic device is classified five different ways to illustrate the sequencing and all-in costs of global expansion. This playbook breaks down the regulatory frameworks in China, South Korea, and Brazil, compares them against the US and EU baselines, and outlines a strategic market-entry sequence.

First-Screen Answer: The Core Obstacles and Suggested Sequence

You cannot directly leverage a US 510(k) or CE mark to register an aesthetic device in China, South Korea, or Brazil because each market applies distinct classification rules, clinical trials, and local representative requirements.

China (NMPA): Both HA dermal fillers and radiofrequency (RF) skin-tightening platforms are regulated under the highest risk category (Class III). The NMPA does not accept foreign clearances. You must conduct local type testing and a mandatory domestic clinical trial within China. The RF Class III up-classification took effect on April 1, 2024, and the revised CMDE HA filler clinical guideline took effect on February 6, 2026.
South Korea (MFDS): Dermal fillers are regulated as Class III or Class IV (the highest tiers). South Korea requires a full technical dossier review (DMF), K-GMP certification (an on-site audit is expected for first-time Class III/IV foreign manufacturers, though document-based review is possible in specific circumstances), and a designated Korea License Holder (KLH) to hold the registration.
Brazil (ANVISA): Fillers are Class III or Class IV under RDC 751/2022. Brazil offers a fast-track reliance route (AREE) under IN 290/2024 that accepts clearances from the US FDA, Health Canada, Australia TGA, and Japan MHLW, but does not accept the EU CE mark for this pathway (EU notified-body approval is not among the four recognized AREE authorities). To register, you must secure local INMETRO electrical safety certification for active devices and appoint a Brazil Registration Holder (BRH).

Recommended Entry Sequence

To minimize time-to-market and regulatory costs:

Anchor in the US/EU first to secure a reference approval. A US 510(k) is the preferred anchor for energy-based devices because it unlocks the Brazil AREE reliance shortcut.
Fan out to Brazil and South Korea next, utilizing your FDA anchor to bypass standard ANVISA pre-market reviews and leveraging MDSAP audits to satisfy K-GMP quality system reviews.
Quarantine China as a long-term, separate track (24 to 48 months), budgeting specifically for domestic clinical trial costs and local NMPA testing.

The Cross-Market Classification Divergence Matrix

The table below maps how the identical HA dermal filler and RF skin-tightening platform are classified and regulated across the five major global markets:

Market	HA Dermal Filler Classification & Pathway	RF Skin Tightening Platform Classification & Pathway	Clinical Data & Testing Requirements	Local Representative Role
United States	Class III (PMA) Product Code: `LMH` Fee: $579,272 (FY2026)	Class II (510(k)) Product Code: `GEX` Fee: $26,067 (FY2026)	PMA requires US pivotal clinical study; 510(k) relies on predicate comparison.	US Agent (Annual registration fee: $11,423)
European Union	Class III (MDR) Swept under Annex XVI (No-medical-purpose)	Class IIb (MDR) Swept under Annex XVI Point 5	Annex XVI requires conformity to Common Specifications (Regulation 2022/2346).	EU Authorised Representative (EC REP)
China	Class III (NMPA) Subject to CMDE 2026 HA Guideline	Class III (NMPA) Up-classified effective April 1, 2024	Mandatory domestic clinical trials and local type testing in NMPA-certified labs.	China Domestic Agent
South Korea	Class III or IV (MFDS) Based on composition/intended use	Class II or III (MFDS) Based on energy output and penetration	Technical dossier review, safety testing, and K-GMP certification (on-site audit expected for first-time Class III/IV foreign manufacturers).	Korea License Holder (KLH)
Brazil	Class III or IV (ANVISA) Regulated under RDC 751/2022	Class II or III (ANVISA) Regulated under RDC 751/2022	Expedited review via AREE reliance if FDA-cleared; otherwise full pre-market review.	Brazil Registration Holder (BRH)

The US Clearance Boom, Safety Gaps, and Injectable Split

To understand the regulatory momentum, we must analyze the data from the world's most mature aesthetic market: the United States.

The Aesthetic Clearance Wave

MedDeviceGuide's quantitative analysis of FDA registration records as of July 2026 reveals a significant surge in aesthetic registrations. Across 50 curated aesthetic product codes, the FDA cleared between 76 and 179 energy-based aesthetic devices annually over the 2020–2025 period:

2020: 76 clearances
2021: 99 clearances
2022: 127 clearances
2023: 129 clearances
2024: 149 clearances
2025: 179 clearances

This represents a 136% increase in annual clearances over five years, driven by first-time registrants and energy-platform innovations. However, a critical methodological caveat must be noted: the broad surgical laser product code (GEX) represents 2,865 of the 3,864 total historical clearances (74.1%) in this cohort. Because the GEX code spans both cosmetic skin-resurfacing lasers and general surgical lasers used in non-aesthetic settings, the absolute count of purely aesthetic clearances is narrower but maintains the same upward trajectory.

The top five applicants in this database represent major laser specialists: Cynosure (89 clearances), Sharplan Lasers (66 clearances), Quanta System (57 clearances), Laserscope (49 clearances), and Candela (47 clearances), highlighting the commercial drive of electro-medical manufacturers.

The Adverse Event Signal

This registration wave has occurred alongside a high volume of post-market safety reports. A review of the FDA's Manufacturer and User Facility Device Experience (MAUDE) database shows that aesthetic devices generate between 45,000 and 50,000 adverse event reports annually:

2022: 50,739 reports
2023: 49,700 reports
2024: 45,298 reports
2025: 46,584 reports

This substantial adverse event volume is the primary regulatory driver behind the tightening of clinical standards and up-classifications worldwide.

The Drug-versus-Device Injectable Split

Another key regulatory distinction lies in the split between different injectable treatments. In the US:

Aesthetic Neuromodulators (such as Botox, Dysport, Xeomin, Jeuveau, and Daxxify) are classified as biologics or drugs. They must clear the FDA under a Biologics License Application (BLA) or a New Drug Application (NDA).
Dermal Fillers (hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid) are classified as Class III medical devices. They must clear the pre-market gate under a Premarket Approval (PMA) application.

This drug-device classification split varies globally, with some jurisdictions regulating dermal fillers under drug laws, further complicating international registration dossiers.

China NMPA's Tightening Aesthetic Frontier (2024–2026)

China represents the most clinical-trial-intensive and reliance-resistant market for medical aesthetics. Over the last two years, the NMPA has closed remaining cosmetic loopholes and instituted strict clinical gates.

RF and Energy Devices: NMPA Type Testing and Up-Classification

Effective April 1, 2024, the NMPA officially up-classified radiofrequency (RF) aesthetic platforms from Class II to Class III. Under NMPA rules, it is illegal to manufacture, import, distribute, or sell RF aesthetic devices in China without a Class III registration certificate.

Before clinical trials can begin, manufacturers must undergo local type testing in China. This is a rigorous process:

NMPA-Accredited Laboratories: All testing must be performed by NMPA-certified domestic laboratories. The manufacturer must ship sample devices, custom test fixtures, and technical software tools to China.
Applicable Standards: The device must meet strict national standards, including GB 9706.1-2020 (general safety requirements for medical electrical equipment), GB 9706.257-2021 (particular requirements for the basic safety and essential performance of high-frequency surgical equipment and RF cosmetic devices), and YY 0505-2012 / GB 9706.102 (electromagnetic compatibility).
Timeline & Cost: Type testing typically takes 6 to 9 months to resolve, costing between $20,000 and $50,000 in laboratory fees, excluding sample shipment and engineering representation.

Dermal Fillers: The CMDE 2026 Clinical Trial Gate

For injectables, the Center for Medical Device Evaluation (CMDE) issued the "Registration Review Guideline for Aesthetic Sodium Hyaluronate Injectable Fillers (2026 Revision)" (Announcement No. 5 of 2026), effective February 6, 2026. This guideline replaces the legacy 2016 version and raises the clinical trial standard:

Mandatory Domestic Clinical Trials: The guideline mandates prospective, randomized, positive-controlled trials conducted at multiple clinical centers within China.
Sample Size and Study Design: Trials are typically designed with on the order of 100 to 120 patients per arm (roughly 200 total patients) to achieve statistical power. The control arm must be a China-approved predicate dermal filler with a similar cross-linking density and composition.
Primary Efficacy Endpoints: Efficacy must be evaluated at 12, 24, and 52 weeks post-treatment using validated aesthetic rating scales (such as the Wrinkle Severity Rating Scale (WSRS) or the Global Aesthetic Improvement Scale (GAIS)). Efficacy evaluations must be conducted by blinded, independent clinical evaluators who were not involved in performing the injections.
Degradation and Safety Tracking: Sponsors must submit product-specific in vivo degradation data, tracking the absorption profile of the hyaluronic acid via imaging or histological methods, alongside detailed safety tracking of delayed-onset tissue reactions, nodules, or inflammatory responses.

Hong Kong's MDACS Expansion (May 13, 2026)

Expanding this tight regulatory border, Hong Kong's Medical Device Division (MDD) updated its GN-00 guidelines (GN-00:2026-1(E)) on May 13, 2026. The update added Appendix 1, which officially lists injectable dermal and mucous-membrane fillers as medical devices under the Medical Device Administrative Control System (MDACS). This ended the legacy practice of importing cosmetic injectables as general consumer goods, aligning Hong Kong's market-entry standards with mainland China and the EU.

South Korea MFDS: KGMP and the Licensed Holder

South Korea is a major exporter and consumer of medical aesthetics, yet its Ministry of Food and Drug Safety (MFDS) maintains high pre-market barriers.

The K-GMP Audit Process for Foreign Manufacturers

The MFDS regulates dermal fillers as Class III or Class IV devices. Before any registration certificate is granted, the manufacturing facility must obtain Korea Good Manufacturing Practice (K-GMP) certification. MFDS decides the audit type (on-site versus document review) on a risk- and pathway-specific basis: for a first-time Class III/IV foreign filler manufacturer an on-site (joint) inspection is the practical default, while document-based review is possible where, for example, another Korean importer already holds a KGMP certificate for the same manufacturer or an MDSAP-based paper audit is granted. Where an on-site audit applies, it covers:

Audit Scope: MFDS inspectors or certified Korean third-party registrars (such as the Korea Testing Laboratory (KTL), Korea Testing & Research Institute (KTR), or Korea Testing Certification (KTC)) will inspect the foreign manufacturing facility.
Physical Inspection Protocol: The physical audit typically spans 4 to 5 working days on-site. Auditors review the cleanroom environmental controls (complying with ISO 14644), sterilization validation records (ISO 11137 for gamma/e-beam radiation or ISO 11135 for ethylene oxide), raw material traceability, batch record consistency, and software change controls. They walk the manufacturing floor, inspect air showers, review HEPA filter maintenance logs, and examine the calibration history of testing apparatus.
K-GMP Preparation Dossier: Foreign manufacturers must compile a detailed quality dossier including the Quality Manual, Cleanroom Validation Reports, Sterilization Validation Dossier, and supplier audit reports for active ingredients.
Validity and Maintenance: The K-GMP certificate is valid for 3 years. Foreign facilities must undergo an on-site or document-based renewal audit triennially to maintain their market access.

Technical File Review (DMF) and Ethnic Sensitivity

All Class III and IV devices must undergo a comprehensive pre-market Technical File Review by MFDS reviewers:

Biocompatibility Data: Complete biocompatibility studies matching ISO 10993-1 requirements must be submitted. This includes cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity, subchronic toxicity, genotoxicity, and local implantation studies.
Ethnic Sensitivity Analysis: The PMDA and MFDS both scrutinize clinical data for ethnic sensitivity. If the primary clinical trial was conducted solely on Caucasian populations, the MFDS may require the sponsor to submit clinical bridging data or an analysis of how the filler performs on Asian skin types (which have different dermal thicknesses and pigment profiles), ensuring there is no elevated risk of hypertrophic scarring or keloid formation.

Brazil ANVISA: RDC 751/2022 and the AREE CE-Rejection Trap

Brazil is the largest medical device market in Latin America. While ANVISA has simplified its quality system reviews, its pre-market registration rules contain a major reliance trap.

RDC 751/2022 Risk Classification Rules

Under RDC No. 751/2022 (which aligned Brazil's risk classification rules with the EU MDR), medical devices are divided into four risk classes. Dermal fillers and energy devices are classified using the following rules:

Rule 8 (Implants): Implantable or long-term surgically invasive devices default to Class III, rising to Class IV when they are absorbed in whole or in large part, or have a biological effect. The common case — an absorbable hyaluronic-acid filler — therefore lands at Class IV, while a non-absorbable filler (e.g., PMMA, CaHA) sits at Class III.
Rule 9 (Active Therapeutical Devices): Energy-based aesthetic platforms (RF, lasers, IPL) are classified as Class II active therapeutical devices by default, rising to Class III when they deliver energy in a potentially hazardous manner.

Brazil's RDC 751/2022 does not contain an EU-MDR "Annex XVI"-style list of products without a medical purpose; a device that lacks a medical purpose (such as a non-medical fat-reduction system) is classified under the general applicable rule rather than under a dedicated cosmetic-device annex.

Step-by-Step AREE Submission Workflow

Brazil’s IN 290/2024 (effective June 3, 2024) establishes the Equivalent Foreign Regulatory Authority (AREE) reliance route. Below is the step-by-step workflow to leverage this shortcut for an FDA-cleared device:

Step 1: Secure the Anchor Clearance. Confirm your US FDA 510(k) or PMA is active.
Step 2: Appoint the BRH. Select a locally-incorporated Brazil Registration Holder (BRH) who holds an active AFE (Operation Authorization) from ANVISA.
Step 3: Gap Analysis & Local Testing. The BRH must translate the technical dossier into Portuguese. For active devices, you must obtain INMETRO certification (incorporating IEC 60601-1 safety standards) and ensure the power plug conforms to local Brazilian standards.
Step 4: Submission. File the Registro application under the AREE code, referencing the FDA clearance.
Step 5: Review. ANVISA will perform a fast-track administrative review, bypassing the standard technical dossier review. The Registro is typically issued within 90 to 120 days instead of the standard 18 to 24 months.

Note: The European CE mark is not among the AREE authorities recognized for medical devices under IN 290/2024. CE-only products are locked out of this fast-track route.

Local active device requirements: INMETRO Certification

Active (powered) electro-medical aesthetic platforms cannot bypass INMETRO Certification. Before submitting the ANVISA dossier, the manufacturer must pass an INMETRO audit. This involves laboratory testing of the device's electrical safety and an audit of the manufacturing facility by a Brazilian accredited certification body (OCP), adding 6 to 12 months to the overall registration timeline.

Japan: The Class IV JMDN Soft-Tissue Filler Path

Japan represents a highly lucrative but exceptionally conservative medical aesthetics market. Dermal fillers face the highest regulatory hurdles in this region.

PMDA Classification and JMDN Code 70441000

The Pharmaceuticals and Medical Devices Agency (PMDA) regulates hyaluronic-acid soft-tissue injection materials under JMDN code 70441000 (officially "hyaluronic-acid-used soft-tissue injection material" — ヒアルロン酸使用軟組織注入材).

Class IV Risk Tier: Hyaluronic-acid fillers are classified as Class IV medical devices (specifically "specially controlled" 高度管理医療機器), the highest risk tier under Japan's Pharmaceutical and Medical Device (PMD) Act.
Pre-Market Approval (Shonin): Class IV devices require a formal pre-market approval (Shonin) issued directly by the Ministry of Health, Labour and Welfare (MHLW) following a detailed scientific review by PMDA.

PMDA Clinical Data and Japanese Patient Data

Japan's PMDA evaluates Class IV implants on whether the submitted clinical data is representative of the Japanese population, on a case-by-case basis. Because dermal fillers are devices (not systemically metabolized drugs), PMDA's ethnic-sensitivity concerns are limited and foreign clinical data can be used:

Japanese Patient Data: Where PMDA concludes that skin thickness, dermal structure, or use-practice differences could affect safety or performance, it expects clinical data that includes Japanese patients to confirm the safety and aesthetic performance translate.
Bridging Studies: If the primary trial was conducted only in the US or Europe, PMDA may request a local bridging study in Japan (the required patient count is product-specific, not a fixed number) to confirm the data can be extrapolated. PMDA pays particular attention to delayed-onset hypersensitivity, nodules, and migration, which are known safety risks for long-duration dermal implants.

The Designated Marketing Authorization Holder (D-MAH)

To register and commercialize a device in Japan, the foreign manufacturer must appoint a Designated Marketing Authorization Holder (D-MAH). The D-MAH must be a licensed Japanese company that possesses three critical regulatory licenses:

General Medical Device Marketing License
Good Quality Practice (GQP) Compliance (ensuring local quality control)
Good Vigilance Practice (GVP) Compliance (responsible for adverse event reporting and recalls)

The D-MAH holds the Shonin approval and acts as the legal liaison between the PMDA and the manufacturer.

PMDA Review Clock and MHLW User Fees

The PMDA Review Timeline: PMDA's published review target for new medical devices is roughly 14 months (about 10 months for priority-review devices); published statistics show new-device reviews completing in around 11 to 12 months at the 80th percentile in recent fiscal years. Total time-to-market is longer once dossier preparation, QMS work, and any local bridging study are included.
The Shonin Dossier Structure: A Class IV Shonin application is organized per the GHTF Summary Technical Documentation (STED) format together with the ICH Common Technical Document (CTD) modules (Modules 1–5) rather than a fixed count of named attachments. The content covers product development history, raw-material specifications, physical/chemical properties, stability data, biocompatibility reports, clinical evaluation data, and risk assessments, with the exact set of required documents varying by product type.
MHLW User Fees: MHLW review fees are significant for novel products. For a new or improved-with-clinical Class IV filler, the combined MHLW + PMDA review and inspection fees commonly run to roughly JPY 10 million to JPY 18 million (about US$70,000 to US$120,000, depending on the review category and exchange rate); lower-tier (generic or no-clinical) Class IV applications cost materially less.
QMS Audit (Ministerial Ordinance No. 169): Manufacturing sites must also conform to Japan's QMS standard, codified under MHLW Ministerial Ordinance No. 169. While Ordinance No. 169 is heavily harmonized with ISO 13485:2016, it contains specific Japanese requirements for document retention, internal organization structure, and reporting channels that the PMDA or a Registered Certified Body (RCB) will audit before granting approval.

All-in Pricing: The In-Country-Representative Cost Trap

When budgeting a global aesthetic launch, manufacturers often look only at the government fees. This approach obscures the true cost of international expansion.

Government Fees vs. Representative Costs

With the exception of the US FDA (where a PMA user fee costs $579,272 and a 510(k) costs $26,067 for FY2026), government pre-market fees are relatively low:

Brazil (ANVISA): Registro fee is approximately BRL 8,509.92 (~$1,700).
Malaysia (MDA): Registration fee ranges from MYR 500 to MYR 3,000 (~$110 to $660).
Vietnam (MoH): Filing fee is approximately VND 0.5M to 3M (~$20 to $120).

These government fees are one-time pass-throughs. The dominant, recurring cost is the fee charged by your mandatory local representative.

Many traditional regulatory consultancies charge variable fees for these representative roles, billing hourly for communication or taking a percentage of local sales. This model penalizes successful manufacturers.

A modern, transparent approach utilizes flat annual fees based on the risk class of the device (typically $1,000 for a US Agent, $2,000 for most standard markets, and $3,000 for high-risk Class III/IV devices). Under this flat-fee model, registering a single energy-based device across four markets (US, EU, South Korea, and Brazil) results in a predictable, flat recurring fee of $9,000 per year, allowing manufacturers to budget their international operations with absolute precision.

One-time preparation fees are handled as fixed project costs, such as $15,000 to $20,000 for a US 510(k) compilation, $30,000 for an EU MDR Clinical Evaluation Report (CER), and $5,000 for a preliminary regulatory-pathway determination to confirm the classification before building the technical files.

Market-Entry Sequencing Playbook

To optimize cash flow and leverage regulatory reliance, aesthetic manufacturers should execute their global rollout in three distinct tiers:

Tier 1: Secure the Anchor Approval

Action: File for approval in the US or EU.
Strategic Goal: Establish a reference technical dossier. For energy-based devices, prioritize the US FDA 510(k) because it is faster (typically cleared in 90–180 days) and serves as the primary currency for downstream reliance. For dermal fillers, the CE mark may be pursued first if a US pivotal clinical trial is financially prohibitive in the short term.

Tier 2: Expand via Reliance and MDSAP

Action: File registrations in Brazil, Canada, Australia, and South Korea.
Strategic Goal: Bypassing standard review timelines. Use your FDA anchor to file in Brazil via the ANVISA AREE pathway. Leverage your MDSAP quality audit report to clear the QMS requirements in Canada, Australia, and Brazil, avoiding multiple overlapping quality inspections. Appoint your local representatives (BRH, KLH) to hold these registrations.

Tier 3: Execute the Trial-Gated Markets

Action: Initiate the China NMPA and Japan PMDA registration pathways.
Strategic Goal: Long-term market access. Initiate local type testing and launch local clinical trials in China under the CMDE 2026 HA filler guideline. Budget 24 to 48 months for these markets and manage them under a separate capital expenditure line, recognizing that prior Western approvals will not bypass the local trial requirements.

Frequently Asked Questions (FAQs)

Does an FDA 510(k) let me register an aesthetic device in China or Brazil?

An FDA 510(k) does not grant direct registration, but its utility differs between the two countries. In China, the NMPA does not accept foreign clearances; you must undergo full local type testing and clinical trials. In Brazil, under IN 290/2024, ANVISA recognizes the FDA as an equivalent authority (AREE). An FDA 510(k) allows you to bypass the standard technical dossier review in Brazil, significantly shortening the registration timeline.

Is a CE mark accepted under Brazil's AREE reliance route?

No. ANVISA's IN 290/2024 equivalent-authority reliance route recognizes the US FDA, Health Canada, Australia TGA, and Japan MHLW, but the European CE mark is not among the recognized AREE authorities for devices. If you only hold a CE mark, you must submit a standard Registro application and undergo ANVISA's full pre-market review.

Why is an HA dermal filler a biologic or drug in some markets and a Class III device in others?

Hyaluronic acid can be regulated differently based on whether a country's regulatory framework categorizes it by its primary mechanical action (filling space) or its potential biological or pharmacological interactions. While the US (FDA) and EU (MDR) regulate HA fillers as devices, other markets regulate them as drug-device combinations or drugs, especially if they contain local anesthetics (like lidocaine) or are cross-linked with novel chemical agents.

How long does it take to register a dermal filler in China versus Korea versus Brazil?

Timelines vary significantly based on clinical requirements. Registration in Brazil via the standard Registro route takes 14 to 24 months (reduced to under 12 months via the AREE route if FDA-cleared). South Korea takes 12 to 24 months due to technical reviews and K-GMP audit scheduling. China requires 24 to 48 months because of the mandatory local clinical trials and CMDE technical review cycles.

Conclusion: Key Strategic Takeaways

Successfully commercializing an aesthetic device globally requires a shift in regulatory strategy from simultaneous filings to structured sequencing. Keep these four conclusions in mind:

Classification dictates the pathway. Do not assume a Class II designation in one market applies globally. RF devices are Class II in the US but Class III in China; fillers are Class III in the US/EU but can be Class IV in Brazil/Korea/Japan.
Leverage reliance asymmetry. Prioritize obtaining a US FDA clearance to unlock Brazil's AREE shortcut, and use MDSAP audits to consolidate quality system compliance.
Budget for the local representative. The government fee is rarely the primary financial barrier. The recurring, annual cost of your mandatory local representative (US Agent, EC REP, BRH, KLH) is the line item that compounds.
Anticipate the clinical trial gate. Plan for a domestic clinical trial in China early (HA fillers under the CMDE 2026 guideline), and assess whether Japan or Korea will request bridging or local data — and ensure your labeling claims align exactly with your validated trial protocols to satisfy the NMPA's 2026 guidelines.

By aligning your international rollout with this cross-market map, you can avoid costly regulatory delays, control your representative costs, and accelerate your time-to-market.